15 May 2020
  • Share

Our client, Duke-NUS, has helped to develop a new, rapid serological test for determining whether someone has had COVID-19.

The test, known as the cPass™, was launched in collaboration with global biotechnology company GenScript and Singapore’s Agency for Science, Technology and Research (A*STAR).

When a person is infected with SARS-CoV-2, their immune response produces antibodies to the virus, some of which are neutralising antibodies (NAbs) capable of blocking binding of the virus to host cells.  The cPass™ is the first test in the world capable of rapidly detecting the presence of NAbs in the blood or serum.

Unlike many existing COVID-19 lab-based antibody tests, the cPass™ does not involve the use of live virus or cells, and therefore does not require processing by highly-skilled operators in biocontainment facilities.

As countries begin to formulate strategy for exit from lockdown, the cPass™ is set to help with our understanding of infection rates and evaluation of humoral protection against the virus.

Read more about these developments: The Straits TimesPR Newswire.

Adam is a Partner and Patent Attorney at Mewburn Ellis. He works with biotech companies to build and manage their patent portfolios, drafting patent applications and co-ordinating prosecution worldwide. Adam has particular experience handling portfolios relating to therapeutics (particularly immunotherapies, including adoptive cellular therapies), antibody technology, diagnostics, and regenerative medicine.
Comments

Sign up to our newsletter: Forward - news, insights and features

Our People

Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.

OUR PEOPLE

Contact Us

We have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany.  We’d love to hear from you, so please get in touch.